Claims for Patent: 9,775,849

Summary for Patent: 9,775,849

Title:	Implants and methods for treating inflammation-mediated conditions of the eye
Abstract:	Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s):	Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/691,079
Patent Claims:	1. A method for treating an inflammation-mediated condition of the eye comprising: implanting into the vitreous of the eye a bioerodible implant consisting of a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant is produced by an extrusion method, wherein the total weight of the implant is about 500-1000 .mu.g, and wherein the inflammation-mediated condition of the eye is macular edema, acute macular degeneration, retinal detachment, or proliferative vitreoretinopathy (PVR). 2. The method of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer. 3. The method of claim 2, wherein the PLGA copolymer is a 50/50 PLGA copolymer. 4. The method of claim 2, wherein the steroidal anti-inflammatory agent comprises about 10% to 90% by weight of the implant. 5. The method of claim 4, wherein the steroidal anti-inflammatory agent comprises about 50% to about 80% by weight of the implant. 6. The method of claim 5, wherein the steroidal anti-inflammatory agent is dexamethasone.